RU2012146083A - Ингибиторы ркс для лечения в-клеточной лимфомы с хроническими активным сигнальным каскадом в-клеточного рецептора - Google Patents
Ингибиторы ркс для лечения в-клеточной лимфомы с хроническими активным сигнальным каскадом в-клеточного рецептора Download PDFInfo
- Publication number
- RU2012146083A RU2012146083A RU2012146083/15A RU2012146083A RU2012146083A RU 2012146083 A RU2012146083 A RU 2012146083A RU 2012146083/15 A RU2012146083/15 A RU 2012146083/15A RU 2012146083 A RU2012146083 A RU 2012146083A RU 2012146083 A RU2012146083 A RU 2012146083A
- Authority
- RU
- Russia
- Prior art keywords
- inhibitor
- cell lymphoma
- dione
- cell
- lymphoma
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title claims abstract 16
- 208000003950 B-cell lymphoma Diseases 0.000 title claims abstract 15
- 108091008875 B cell receptors Proteins 0.000 title claims abstract 8
- 230000001684 chronic effect Effects 0.000 title 1
- 102000003923 Protein Kinase C Human genes 0.000 claims abstract 13
- 230000019491 signal transduction Effects 0.000 claims abstract 7
- 239000003814 drug Substances 0.000 claims abstract 6
- 229940124302 mTOR inhibitor Drugs 0.000 claims abstract 6
- 239000003628 mammalian target of rapamycin inhibitor Substances 0.000 claims abstract 6
- ARAWNHPXQUHVIU-UHFFFAOYSA-N 3-[2-chloro-7-[(dimethylamino)methyl]naphthalen-1-yl]-4-[7-[2-(2-methoxyethoxy)ethoxy]-1h-indol-3-yl]pyrrole-2,5-dione Chemical compound C1=C(CN(C)C)C=C2C(C3=C(C(NC3=O)=O)C=3C=4C=CC=C(C=4NC=3)OCCOCCOC)=C(Cl)C=CC2=C1 ARAWNHPXQUHVIU-UHFFFAOYSA-N 0.000 claims abstract 4
- 229940122245 Janus kinase inhibitor Drugs 0.000 claims abstract 4
- 239000012828 PI3K inhibitor Substances 0.000 claims abstract 4
- 239000008177 pharmaceutical agent Substances 0.000 claims abstract 4
- 229940043441 phosphoinositide 3-kinase inhibitor Drugs 0.000 claims abstract 4
- 201000006845 reticulosarcoma Diseases 0.000 claims abstract 4
- 208000029922 reticulum cell sarcoma Diseases 0.000 claims abstract 4
- OAVGBZOFDPFGPJ-UHFFFAOYSA-N sotrastaurin Chemical group C1CN(C)CCN1C1=NC(C=2C(NC(=O)C=2C=2C3=CC=CC=C3NC=2)=O)=C(C=CC=C2)C2=N1 OAVGBZOFDPFGPJ-UHFFFAOYSA-N 0.000 claims abstract 4
- 229950005814 sotrastaurin Drugs 0.000 claims abstract 4
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims abstract 3
- KLSCBNKMNKJFBO-UHFFFAOYSA-N 3-[3-(4,7-diazaspiro[2.5]octan-7-yl)isoquinolin-1-yl]-4-(7-methyl-1h-indol-3-yl)pyrrole-2,5-dione Chemical compound C=1NC=2C(C)=CC=CC=2C=1C(C(NC1=O)=O)=C1C(C1=CC=CC=C1C=1)=NC=1N(C1)CCNC21CC2 KLSCBNKMNKJFBO-UHFFFAOYSA-N 0.000 claims abstract 2
- 101150020891 PRKCA gene Proteins 0.000 claims abstract 2
- DXASQZJWWGZNSF-UHFFFAOYSA-N n,n-dimethylmethanamine;sulfur trioxide Chemical group CN(C)C.O=S(=O)=O DXASQZJWWGZNSF-UHFFFAOYSA-N 0.000 claims abstract 2
- 150000003839 salts Chemical class 0.000 claims abstract 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- WAKGEHXTOOFEAE-UHFFFAOYSA-N 3-(1h-indol-3-yl)-4-(2-piperazin-1-ylquinazolin-4-yl)pyrrole-2,5-dione Chemical compound C=1NC2=CC=CC=C2C=1C=1C(=O)NC(=O)C=1C(C1=CC=CC=C1N=1)=NC=1N1CCNCC1 WAKGEHXTOOFEAE-UHFFFAOYSA-N 0.000 claims 1
- BUROJSBIWGDYCN-GAUTUEMISA-N AP 23573 Chemical compound C1C[C@@H](OP(C)(C)=O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 BUROJSBIWGDYCN-GAUTUEMISA-N 0.000 claims 1
- HKVAMNSJSFKALM-GKUWKFKPSA-N Everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-GKUWKFKPSA-N 0.000 claims 1
- CBPNZQVSJQDFBE-FUXHJELOSA-N Temsirolimus Chemical group C1C[C@@H](OC(=O)C(C)(CO)CO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 CBPNZQVSJQDFBE-FUXHJELOSA-N 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- GOJNABIZVJCYFL-UHFFFAOYSA-M dimethylphosphinate Chemical compound CP(C)([O-])=O GOJNABIZVJCYFL-UHFFFAOYSA-M 0.000 claims 1
- 229960005167 everolimus Drugs 0.000 claims 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 229960001302 ridaforolimus Drugs 0.000 claims 1
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 claims 1
- 229960000235 temsirolimus Drugs 0.000 claims 1
- QFJCIRLUMZQUOT-UHFFFAOYSA-N temsirolimus Natural products C1CC(O)C(OC)CC1CC(C)C1OC(=O)C2CCCCN2C(=O)C(=O)C(O)(O2)C(C)CCC2CC(OC)C(C)=CC=CC=CC(C)CC(C)C(=O)C(OC)C(O)C(C)=CC(C)C(=O)C1 QFJCIRLUMZQUOT-UHFFFAOYSA-N 0.000 claims 1
- 210000003719 b-lymphocyte Anatomy 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 125000004194 piperazin-1-yl group Chemical group [H]N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 abstract 1
- 125000004546 quinazolin-4-yl group Chemical group N1=CN=C(C2=CC=CC=C12)* 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/499—Spiro-condensed pyrazines or piperazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US31901310P | 2010-03-30 | 2010-03-30 | |
| US61/319,013 | 2010-03-30 | ||
| US201061425525P | 2010-12-21 | 2010-12-21 | |
| US61/425,525 | 2010-12-21 | ||
| PCT/EP2011/054709 WO2011120911A1 (en) | 2010-03-30 | 2011-03-28 | Pkc inhibitors for the treatment of b-cell lymphoma having chronic active b-cell-receptor signalling |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2012146083A true RU2012146083A (ru) | 2014-05-10 |
Family
ID=44710357
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2012146083/15A RU2012146083A (ru) | 2010-03-30 | 2011-03-28 | Ингибиторы ркс для лечения в-клеточной лимфомы с хроническими активным сигнальным каскадом в-клеточного рецептора |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US8748428B2 (https=) |
| EP (1) | EP2552428A1 (https=) |
| JP (1) | JP2013523678A (https=) |
| KR (2) | KR101461767B1 (https=) |
| CN (1) | CN102821759A (https=) |
| AR (1) | AR080737A1 (https=) |
| AU (1) | AU2011234644B2 (https=) |
| BR (1) | BR112012024585A2 (https=) |
| CA (1) | CA2795456A1 (https=) |
| MX (1) | MX2012011341A (https=) |
| RU (1) | RU2012146083A (https=) |
| WO (1) | WO2011120911A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES3018133T3 (en) | 2011-11-30 | 2025-05-14 | Univ Emory | Jak inhibitors for use in the prevention or treatment of a viral disease caused by a coronaviridae |
| KR101723786B1 (ko) | 2014-03-28 | 2017-04-06 | 가톨릭대학교 산학협력단 | Ｉｌ―２１을 발현하는 중간엽 줄기세포를 포함하는 ｂ 세포 림프종 예방 또는 치료용 조성물 |
| JO3589B1 (ar) | 2014-08-06 | 2020-07-05 | Novartis Ag | مثبطات كيناز البروتين c وطرق استخداماتها |
| AU2017295858A1 (en) | 2016-07-14 | 2019-01-24 | Mingsight Pharmaceuticals, Inc. | Treatment of cancer |
| CN110496223B (zh) * | 2018-05-17 | 2021-09-10 | 复旦大学附属肿瘤医院 | 一种治疗非霍奇金氏淋巴瘤的药物组合物 |
| WO2020092924A1 (en) * | 2018-11-02 | 2020-05-07 | Board Of Regents, The University Of Texas System | Combination therapy for the treatment of egfr tyrosine kinase inhibitor resistant cancer |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5489608A (en) | 1989-12-21 | 1996-02-06 | Goedecke Aktiengesellschaft | Indolocarbazole derivatives and the use thereof |
| US5475085A (en) | 1991-02-07 | 1995-12-12 | Molecumetics, Ltd. | Conformationally restricted mimetics of beta turns and beta bulges and peptides containing the same |
| PT657458E (pt) | 1993-12-07 | 2002-02-28 | Lilly Co Eli | Inibidores de proteina cinase c |
| US5545636A (en) | 1993-12-23 | 1996-08-13 | Eli Lilly And Company | Protein kinase C inhibitors |
| CA2179650C (en) | 1993-12-23 | 2007-10-30 | William Francis Heath, Jr. | Bisindolemaleimides and their use as protein kinase c inhibitors |
| SI0776895T1 (en) | 1995-11-20 | 1999-04-30 | Eli Lilly And Company | Protein kinase C inhibitor |
| EP2070921A1 (en) * | 2000-11-07 | 2009-06-17 | Novartis Ag | Indolylmaleimide derivatives as protein kinase c inhibitors |
| US6645970B2 (en) * | 2000-11-07 | 2003-11-11 | Novartis Ag | Indolylmaleimide derivatives |
| PT1478648E (pt) | 2002-02-01 | 2014-07-15 | Ariad Pharma Inc | Compostos contendo fósforo e suas utilizações |
| TW200918046A (en) | 2002-04-03 | 2009-05-01 | Novartis Ag | Indolylmaleimide derivatives |
| BRPI0409263A (pt) | 2003-04-09 | 2006-03-28 | Millennium Pharm Inc | composto; composição farmacêutica; método para tratar uma doença mediada por ikk e método para inibir ikk em um paciente que dele necessita |
| GB0308466D0 (en) | 2003-04-11 | 2003-05-21 | Novartis Ag | Organic compounds |
| WO2005041953A1 (en) | 2003-10-24 | 2005-05-12 | Eli Lilly And Company | Bisindolyl maleimides useful for treating prostate cancer and akt-mediated diseases |
| EP1799699A1 (en) | 2004-10-13 | 2007-06-27 | Wyeth | Analogs of 17-hydroxywortmannin as pi3k inhibitors |
| CA2599320A1 (en) | 2005-02-25 | 2006-08-31 | Kudos Pharmaceuticals Limited | Hydrazinomethyl, hydr zonomethyl and 5-membered heterocylic compounds which act as mtor inhibitors and their use as anti cancer agents |
| JP2008531538A (ja) | 2005-02-25 | 2008-08-14 | クドス ファーマシューティカルズ リミテッド | ２，４−ジアミノ−ピリドピリミジン誘導体とｍＴＯＲ阻害剤としてのその使用 |
| GB0510390D0 (en) | 2005-05-20 | 2005-06-29 | Novartis Ag | Organic compounds |
| MX2008000463A (es) | 2005-07-11 | 2008-03-11 | Novartis Ag | Derivados de indolil-maleimida. |
| JP5191391B2 (ja) | 2005-11-01 | 2013-05-08 | ターゲジェン インコーポレーティッド | キナーゼのビ−アリールメタ−ピリミジン阻害剤 |
| JP5161102B2 (ja) | 2005-11-22 | 2013-03-13 | クドス ファーマシューティカルズ リミテッド | ｍＴＯＲ阻害剤としてのピリドピリミジン、ピラゾピリミジンおよびピリミドピリミジン誘導体 |
| GB0526246D0 (en) | 2005-12-22 | 2006-02-01 | Novartis Ag | Organic compounds |
| EP1979325A1 (en) | 2006-01-11 | 2008-10-15 | AstraZeneca AB | Morpholino pyrimidine derivatives and their use in therapy |
| CA2659851C (en) | 2006-08-23 | 2014-02-25 | Kudos Pharmaceuticals Limited | 2-methylmorpholine pyrido-, pyrazo- and pyrimido-pyrimidine derivatives as mtor inhibitors |
| MX2009005950A (es) | 2006-12-07 | 2009-10-12 | Genentech Inc | Compuestos inhibidores de fosfoinositido 3-quinasas y metodos de uso. |
| AR066879A1 (es) | 2007-06-08 | 2009-09-16 | Novartis Ag | Derivados de quinoxalina como inhibidores de la actividad de cinasa de tirosina de las cinasas janus |
| EP2205242B1 (en) | 2007-09-12 | 2015-04-15 | Genentech, Inc. | Combinations of phosphoinositide 3-kinase inhibitor compounds and chemotherapeutic agents, and methods of use |
| JP5348725B2 (ja) | 2007-10-25 | 2013-11-20 | ジェネンテック， インコーポレイテッド | チエノピリミジン化合物の製造方法 |
| CA2730930C (en) | 2008-07-16 | 2015-01-13 | Pharmacyclics, Inc. | Inhibitors of bruton's tyrosine kinase for the treatment of solid tumors |
-
2011
- 2011-03-28 KR KR1020127025582A patent/KR101461767B1/ko not_active Expired - Fee Related
- 2011-03-28 AU AU2011234644A patent/AU2011234644B2/en not_active Ceased
- 2011-03-28 EP EP11713996A patent/EP2552428A1/en not_active Withdrawn
- 2011-03-28 CA CA2795456A patent/CA2795456A1/en not_active Abandoned
- 2011-03-28 US US13/073,652 patent/US8748428B2/en not_active Expired - Fee Related
- 2011-03-28 MX MX2012011341A patent/MX2012011341A/es not_active Application Discontinuation
- 2011-03-28 KR KR1020147022716A patent/KR20140107685A/ko not_active Withdrawn
- 2011-03-28 WO PCT/EP2011/054709 patent/WO2011120911A1/en not_active Ceased
- 2011-03-28 JP JP2013501783A patent/JP2013523678A/ja active Pending
- 2011-03-28 CN CN2011800155365A patent/CN102821759A/zh active Pending
- 2011-03-28 RU RU2012146083/15A patent/RU2012146083A/ru not_active Application Discontinuation
- 2011-03-28 BR BR112012024585A patent/BR112012024585A2/pt not_active IP Right Cessation
- 2011-03-30 AR ARP110101038A patent/AR080737A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MX2012011341A (es) | 2012-11-12 |
| EP2552428A1 (en) | 2013-02-06 |
| WO2011120911A1 (en) | 2011-10-06 |
| JP2013523678A (ja) | 2013-06-17 |
| AU2011234644B2 (en) | 2014-07-17 |
| AU2011234644A1 (en) | 2012-10-11 |
| US20110245256A1 (en) | 2011-10-06 |
| KR101461767B1 (ko) | 2014-11-13 |
| KR20140107685A (ko) | 2014-09-04 |
| KR20120133389A (ko) | 2012-12-10 |
| CN102821759A (zh) | 2012-12-12 |
| AR080737A1 (es) | 2012-05-02 |
| BR112012024585A2 (pt) | 2016-05-31 |
| US8748428B2 (en) | 2014-06-10 |
| CA2795456A1 (en) | 2011-10-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Kocak et al. | Targeting autophagy in disease: established and new strategies | |
| Fasolo et al. | Targeting mTOR pathways in human malignancies | |
| García-Echeverría | Allosteric and ATP-competitive kinase inhibitors of mTOR for cancer treatment | |
| RU2012146083A (ru) | Ингибиторы ркс для лечения в-клеточной лимфомы с хроническими активным сигнальным каскадом в-клеточного рецептора | |
| AR088730A1 (es) | Uso de 2,3-dihidroimidazo[1,2-c]quinazolinas sustituidas | |
| RU2014124184A (ru) | Комбинация ингибитора фосфоинозитид-3-киназы и модулятора пути янус-киназы 2 - проводника сигнала и активатора транскрипции 5 | |
| AU2021225157A1 (en) | Combination therapy of tetracyclic quinolone analogs for treating cancer | |
| AU2016262079A1 (en) | Combination of analogs or derivatives of dianhydrogalactitol with platinum-containing antineoplastic agents to treat cancer | |
| JP2010522750A5 (https=) | ||
| AU2009225434B2 (en) | Treatment with opioid antagonists and mTOR inhibitors | |
| CN106659716A (zh) | 阿吡莫德组合物及其使用方法 | |
| JP2018510869A (ja) | 置換２，３−ジヒドロイミダゾ［１，２−ｃ］キナゾリンを含んでいる組合せ | |
| A. Sabbah et al. | Dual inhibitors of PI3K/mTOR or mTOR-selective inhibitors: which way shall we go? | |
| CN107249638A (zh) | 阿匹莫德用于治疗肾癌 | |
| Vu et al. | Target of rapamycin signaling in leukemia and lymphoma | |
| JP2013523678A5 (https=) | ||
| JP2021501140A5 (https=) | ||
| CN112512525A (zh) | 治疗癌症的方法 | |
| CN114423457A (zh) | 治疗脾肿大的方法 | |
| RU2012148706A (ru) | Комбинация органичемких соединений | |
| Porcelli et al. | Synergistic antiproliferative and antiangiogenic effects of EGFR and mTOR inhibitors | |
| KR20250151363A (ko) | 골수증식성 신생물의 치료 방법 | |
| Zhang et al. | Autophagy and cell death: Antitumor drugs targeting autophagy | |
| WO2018163051A1 (en) | Methods of treatment of cancer with reduced ubb expression | |
| CN108024987A (zh) | 用于治疗癌症的二去水卫矛醇的类似物或衍生物与含铂抗肿瘤药物的组合 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20150629 |